C12N 2830/15
Chimeric enhancer/promoter combination
Official title: chimeric enhancer/promoter combination
C12N2830/15 (Chimeric enhancer/promoter combination) appears on 401 US grants and 548 published applications in this corpus.
Search patents in C12N- Granted patents
- 401
- Published applications
- 548
- Assignees
- 349
- Inventors
- 1,192
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 5 | 0 |
| 1996 | 5 | 0 |
| 1997 | 8 | 0 |
| 1998 | 30 | 0 |
| 1999 | 12 | 0 |
| 2000 | 13 | 0 |
| 2001 | 20 | 2 |
| 2002 | 17 | 29 |
| 2003 | 16 | 51 |
| 2004 | 6 | 36 |
| 2005 | 13 | 37 |
| 2006 | 18 | 39 |
| 2007 | 23 | 19 |
| 2008 | 17 | 18 |
| 2009 | 18 | 18 |
| 2010 | 14 | 18 |
| 2011 | 11 | 12 |
| 2012 | 14 | 13 |
| 2013 | 11 | 9 |
| 2014 | 16 | 9 |
| 2015 | 4 | 7 |
| 2016 | 8 | 13 |
| 2017 | 8 | 15 |
| 2018 | 9 | 16 |
| 2019 | 9 | 19 |
| 2020 | 11 | 14 |
| 2021 | 9 | 21 |
| 2022 | 9 | 19 |
| 2023 | 14 | 19 |
| 2024 | 9 | 34 |
| 2025 | 10 | 41 |
| 2026 | 6 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Synthetic promoters for gene therapy and protein expression14 Jul 2026US 12,680,111 B2University of Massachusetts
- Artificial expression constructs for selectively modulating gene expression in non-neuronal brain cells16 Jun 2026US 12,655,444 B2Allen Institute
- Polynucleotide for physiological expression in T-cells19 May 2026US 12,630,843 B2FundacióN PúBlica Andaluza Progreso Y Salud
- Methods and compositions for reducing the immunogenicity of chimeric notch receptors5 May 2026US 12,617,825 B2Cell Design Labs, Inc.
- DNA vectors and elements for sustained gene expression in eukaryotic cells28 Apr 2026US 12,612,646 B2Dna Twopointo Inc.
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Promoter for gene expression in retinal cells, and vector system comprising same1 Oct 2026US 2026/0295081 A1Korea Research Institute of Bioscience and Biotechnology
- Gene therapy for treating mucopolysaccharidosis type ii1 Oct 2026US 2026/0295085 A1The Trustees of the University of Pennsylvania
- Gene therapy for treatment of protein misfolding diseases1 Oct 2026US 2026/0295093 A1Research Institute At Nationwide Children's Hospital
Most cited
By later US patents
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- Packaging systems for human recombinant adenovirus to be used in gene therapy267US 5,994,128 AIntrogene B.V. · 1999
- Transgenic bovine266US 5,741,957 APharming B.V. · 1998
- Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease201US 5,387,742 AScios Nova Inc. · 1995